GlycoKnow Ovarian: a Glycoprotein-based, Serum Diagnostic to Distinguish Ovarian Cancers from Benign Pelvic Masses.

Objective: Blood-based biomarkers offer an unprecedented opportunity to realize the promise of precision medicine in improving diagnostic workflows. Previous peer-reviewed studies have established the association of the circulating glycoproteome with ovarian cancer. Here a glycoproteomic classifier was built, tested, and applied to both internal and external validation cohorts to distinguish malignant from benign pelvic masses.

Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.

Background: There is a need for diagnostic tests for screening, triaging and staging of epithelial ovarian cancer (EOC). Glycoproteomics of blood samples has shown promise for biomarker discovery.

Methods: We applied glycoproteomics to serum of people with EOC or benign pelvic masses and healthy controls.

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy.

The clinical success of immune-checkpoint inhibitors (ICI) in both resected and metastatic melanoma has confirmed the validity of therapeutic strategies that boost the immune system to counteract cancer. However, half of patients with metastatic disease treated with even the most aggressive regimen do not derive durable clinical benefit. Thus, there is a critical need for predictive biomarkers that can identify individuals who are unlikely to benefit with high accuracy so that these patients may be spared the toxicity of treatment without the likely benefit of response.

Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19.

Glycosylation is the most common form of post-translational modification of proteins, critically affecting their structure and function. Using liquid chromatography and mass spectrometry for high-resolution site-specific quantification of glycopeptides coupled with high-throughput artificial intelligence-powered data processing, we analyzed differential protein glycoisoform distributions of 597 abundant serum glycopeptides and nonglycosylated peptides in 50 individuals who had been seriously ill with COVID-19 and in 22 individuals who had recovered after an asymptomatic course of COVID-19. As additional comparison reference phenotypes, we included 12 individuals with a history of infection with a common cold coronavirus, 16 patients with bacterial sepsis, and 15 healthy subjects without history of coronavirus exposure.

Support for Transgender Military Service from Active Duty United States Military Personnel.

Introduction: Most transgender individuals are banned from serving in and joining the U.S. military.